WHO ICTRP trial
A clinical study of CD19-chimeric-antigen-receptor-tranduced T cells in the…
ChiCTR-OOC-16007779 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR-OOC-16007779 |
|---|---|
| Public title | A clinical study of CD19-chimeric-antigen-receptor-tranduced T cells in the treatment of chemotherapy resistant or refractory B cell malignancy |
| Scientific title | A clinical study of CD19-chimeric-antigen-receptor-tranduced T cells in the treatment of chemotherapy resistant or refractory B cell malignancy |
| Primary sponsor | Zhujiang Hospital of Southern Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Observational study |
| Phase | Other |
| Countries | China |
| Conditions | Chemotherapy resistant or refractory B cell malignancy |
| Interventions | experimental group:therapy by CART |
| Registration date | Jan 17, 2016 |
| Target size | experimental group:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: